Blucora Inc (NASDAQ:BCOR) up by 21.06%, Sequenom Inc (NASDAQ:SQNM)

Posted by Ryan Mandell May 5, 2013 0 Comment 1265 views


Northern, WI 05/05/2013 (GDPInsider) – Blucora Inc (NASDAQ:BCOR): In Friday’s trading session there was a healthy 21.06% rise in Blucora Inc (NASDAQ:BCOR) shares. The shares had an opening price of $17.00 which touched an intraday price of $18.13 and closed at $16.68 per share. Over 3.25M shares were traded in Friday’s trading session which was above the average volume range of 0.495M which was measured over the last 30 days.

Blucora Inc (NASDAQ:BCOR) announced its earnings results last on Thursday 2 May. The company has reported quarterly earnings of $0.95 per share which topped analyst estimates of $0.94. Blucora’s quarterly revenue was $165.34 million in comparison to the projected $158.71 which was an increase of 42.9% from the same quarter, last year.

The company was formerly known as InfoSpace Inc. it is an online solutions provider for business and consumer segments. It owns as well as operates two different internet businesses. Via its InfoSpace business it provides online monetization and search solutions. Its network includes over 100 global partners.

How Should Investors Trade BCOR Now? Get the latest trends and data here.

Sequenom Inc (NASDAQ:SQNM): In Friday’s trading session there was a dip of 1.67% in Sequenom, Inc (NASDAQ:SQNM) shares. The shares had an opening price of $3.62 which touched an intraday price of $3.63 and closed at $3.42. Over 3.33M shares were traded in Friday’s trading session which was above the average volume range of 2.20M which was measured over the last 30 days.

On Mar 21 the company announced that the SCCM- Sequenom Center for Molecular Medicine has launched a highly advanced carrier screen test for cystic fibrosis that is branded as Hedidi-T. Physicians can now order the LDT or Laboratory Developed Test and can be used as a testing device. This test analyzes 136 different mutations. Five of these variants have already been proven to have clinical relevance in causing CF. these integrate disease-causing mutations that have been selected from the John Hopkins’ CFTR2 database

Sequenom, Inc (NASDAQ:SQNM) manufactures sequencing and detection equipment. The company provides products that are used for genetic analysis. These are used in translating genomic science into solutions that are used in biomedical research, agricultural applications and molecular medicine.

Is SQNM a solid investment at these levels? Get valuable updates and exclusive insights here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment